Email updates

Keep up to date with the latest news and content from BMC Medical Genomics and BioMed Central.

Open Access Highly Accessed Research article

Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes

Ji-Hoon Cho1, Richard Gelinas12, Kai Wang1, Alton Etheridge1, Melissa G Piper3, Kara Batte3, Duaa Dakhlallah3, Jennifer Price2, Dan Bornman2, Shile Zhang1, Clay Marsh3 and David Galas124*

Author affiliations

1 Institute for Systems Biology, Seattle WA USA

2 Division of Health and Life Sciences, Battelle Memorial Institute, Columbus OH USA

3 Division of Pulmonary, Allergy, Critical Care, Sleep Medicine, Davis Heart and Lung Research Institute, Columbus, OH USA

4 University of Luxembourg, 7220 Walfer, Luxembourg

For all author emails, please log on.

Citation and License

BMC Medical Genomics 2011, 4:8  doi:10.1186/1755-8794-4-8

Published: 17 January 2011

Abstract

Background

The molecular pathways involved in the interstitial lung diseases (ILDs) are poorly understood. Systems biology approaches, with global expression data sets, were used to identify perturbed gene networks, to gain some understanding of the underlying mechanisms, and to develop specific hypotheses relevant to these chronic lung diseases.

Methods

Lung tissue samples from patients with different types of ILD were obtained from the Lung Tissue Research Consortium and total cell RNA was isolated. Global mRNA and microRNA were profiled by hybridization and amplification-based methods. Differentially expressed genes were compiled and used to identify critical signaling pathways and potential biomarkers. Modules of genes were identified that formed a regulatory network, and studies were performed on cultured cells in vitro for comparison with the in vivo results.

Results

By profiling mRNA and microRNA (miRNA) expression levels, we found subsets of differentially expressed genes that distinguished patients with ILDs from controls and that correlated with different disease stages and subtypes of ILDs. Network analysis, based on pathway databases, revealed several disease-associated gene modules, involving genes from the TGF-β, Wnt, focal adhesion, and smooth muscle actin pathways that are implicated in advancing fibrosis, a critical pathological process in ILDs. A more comprehensive approach was also adapted to construct a putative global gene regulatory network based on the perturbation of key regulatory elements, transcription factors and microRNAs. Our data underscores the importance of TGF-β signaling and the persistence of smooth muscle actin-containing fibroblasts in these diseases. We present evidence that, downstream of TGF-β signaling, microRNAs of the miR-23a cluster and the transcription factor Zeb1 could have roles in mediating an epithelial to mesenchymal transition (EMT) and the resultant persistence of mesenchymal cells in these diseases.

Conclusions

We present a comprehensive overview of the molecular networks perturbed in ILDs, discuss several potential key molecular regulatory circuits, and identify microRNA species that may play central roles in facilitating the progression of ILDs. These findings advance our understanding of these diseases at the molecular level, provide new molecular signatures in defining the specific characteristics of the diseases, suggest new hypotheses, and reveal new potential targets for therapeutic intervention.